Vienna, Austria

ESTRO 2023

Session Item

May 14
10:30 - 11:30
Hall A
Haematology - CNS
Giuseppe Minniti, Italy;
Lena Specht, Denmark
Proffered Papers
10:50 - 11:00
Consolidation patterns and associated outcomes for a large cohort of primary CNS lymphoma patients
Brandon Imber, USA


Consolidation patterns and associated outcomes for a large cohort of primary CNS lymphoma patients

Brandon Imber1, Kathryn Tringale1, Michael Scordo2, Joachim Yahalom1, Christian Grommes3

1Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, New York, USA; 2Memorial Sloan Kettering Cancer Center, Department of Medicine, Adult Bone Marrow Transplant Service, New York, USA; 3Memorial Sloan Kettering Cancer Center, Department of Neurology/Neuro-oncology, New York, USA

Show Affiliations
Purpose or Objective

There are several acceptable consolidation strategies for primary central nervous system lymphoma (PCNSL) after induction chemoimmunotherapy like whole-brain radiotherapy [≤24Gy reduced-dose, RD-WBRT vs >24Gy standard-dose, SD-WBRT], cytarabine or autologous stem cell transplant [ASCT]. We analyzed patterns of contemporary use and associated outcomes in a large cohort.

Material and Methods

Patients with PCNSL (diffuse large B-cell subtype) from 1983-2020 were identified from an institutional database. Longitudinal consolidation patterns were analyzed using Fisher exact test. Consolidation strategies and outcomes were stratified by decade and MSKCC recursive partitioning analysis (RPA) class 1 (age<50), 2 (age≥50, KPS≥70) or 3 (age≥50, KPS<70). Clinicodemographic associations with consolidation strategy were analyzed by multinomial logistic regression. Progression free (PFS) and overall survival (OS) were analyzed by Kaplan Meier and proportional hazards from consolidation date.


Of 645 evaluated, 559 were eligible and 385 (69%) received consolidation. Median follow-up was 7.4 years and median OS was 4.8 years. Median age was 63 years (IQR 54-72); most (n=321, 57%) were RPA class 2. Over the study period, there was significant change in consolidation patterns with declining use of WBRT plus cytarabine (61% in 1990s vs. 12% in 2010s) and rising utilization of ASCT (4% in 1990s vs. 32% in 2010s) and cytarabine alone (27% in 1990s vs. 52% in 2010s) [Fig A, p<0.001]. This temporal evolution was seen across RPA classes, with increased cytarabine usage for greater RPA in modern years (Fig B-D). On multivariable logistic regression, compared to RPA class 1, class 2 was significantly less likely to receive ASCT (OR 0.23, p=0.001), RD-WBRT (OR 0.31 p=0.02) or SD-WBRT (OR 0.08, p<0.001) vs. cytarabine. Those with partial response to induction were also less likely to receive ASCT (OR 0.36, p=0.02). Among the 351 with complete response to consolidation, on multivariable analysis, only receipt of R-MPV induction was associated with better PFS (HR 0.5 p=0.006). There was no significant PFS association with any consolidation strategy. RPA class 3 was associated with poorer OS (HR 1.9, p=0.03). For RPA class 1 and 2, among all consolidation strategies, patients treated with ASCT and RD-WBRT had similar, best OS outcomes (Fig E-G). For RPA class 1, median OS was not reached for ASCT or RD-WBRT and 2.5 years post cytarabine. For RPA class 2, median OS was 9.4 years post ASCT, 6.7 years post RD-WBRT and cytarabine and 3.0 years post cytarabine alone.


There has been significant change in consolidation approach for PCNSL with decreased utilization of WBRT plus cytarabine and increased utilization of cytarabine alone. However, RD-WBRT is associated with excellent outcomes across RPA classes. In light of preliminary data from the ongoing RTOG 1114 trial demonstrating improved PFS and no early neurotoxicity signal, RD-WBRT could be more strongly considered, particularly for higher RPA classes.